{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:35:05Z","timestamp":1790112905328,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nf0101626"],"award-info":[{"award-number":["JP21nf0101626"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.04.054","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T04:41:20Z","timestamp":1652416880000},"page":"3721-3726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings"],"prefix":"10.1016","volume":"40","author":[{"given":"Satoshi","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.04.054_b0005","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https:\/\/covid19.who.int Last accessed: October 9, 2021."},{"key":"10.1016\/j.vaccine.2022.04.054_b0010","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape. Available from: https:\/\/covid19.who.int Last accessed: October 9, 2021."},{"issue":"35","key":"10.1016\/j.vaccine.2022.04.054_b0015","doi-asserted-by":"crossref","first-page":"E1400","DOI":"10.1503\/cmaj.1095959","article-title":"What\u2019s the evidence for COVID-19 booster shots?","volume":"193","author":"Vogel","year":"2021","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2022.04.054_b0020","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.2147\/IDR.S320658","article-title":"Detection of representative mutant strains and a case of prolonged infection by SARS-CoV-2 with spike 69\/70 deletion in Japan","volume":"14","author":"Takano","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2022.04.054_b0025","unstructured":"WMA Declaration of Helsinki \u2013 Ethical principles for medical research involving human subjects. Available from: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/ Last accessed: October 9, 2021."},{"key":"10.1016\/j.vaccine.2022.04.054_b0030","unstructured":"Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health-related Research Involving Humans. Available from: https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf Last accessed: October 9, 2021."},{"key":"10.1016\/j.vaccine.2022.04.054_b0035","unstructured":"International Council for Harmonisation. Efficacy guidelines. Available from: https:\/\/www.ich.org\/page\/efficacy-guidelines Last accessed: October 9, 2021."},{"key":"10.1016\/j.vaccine.2022.04.054_b0040","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.vaccine.2022.04.054_b0045","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.054_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pep.2016.02.014","article-title":"Characterization of an Sf-rhabdovirus-negative S. frugiperda cell line as an alternative host for recombinant protein production in the baculovirus-insect cell system","volume":"122","author":"Maghodia","year":"2016","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2022.04.054_b0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/pathogens10030355","article-title":"Squalene-based influenza vaccine adjuvants and their impact on the hemagglutinin-specific b cell response","volume":"10","author":"Nguyen-Contant","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.04.054_b0060","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"Dispinseri","year":"2021","journal-title":"Nature Comm"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.054_b0065","first-page":"116","article-title":"COVID-19 disease and interferon-\u03b3: has it a protective impact on mortality?","volume":"43","author":"Husseini","year":"2021","journal-title":"Erciyes Med J"},{"key":"10.1016\/j.vaccine.2022.04.054_b0070","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1473-3099(21)00147-X","article-title":"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1\u20132, dose-ranging study","volume":"21","author":"Goepfert","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.054_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581807","article-title":"An effective COVID-19 vaccine needs to engage T cells","volume":"11","author":"Sauer","year":"2020","journal-title":"Front Immunol"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2022.04.054_b0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12026-014-8534-z","article-title":"T cell-mediated immune response to respiratory coronaviruses","volume":"59","author":"Channappanavar","year":"2014","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.054_b0085","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jmii.2020.03.015","article-title":"Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection","volume":"53","author":"Lin","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"7821","key":"10.1016\/j.vaccine.2022.04.054_b0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:13:01Z","timestamp":1759403581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22004947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":18,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22004947"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}